;PMID: 11554431
;source_file_821.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..58] = [t:0..58]
;1)sentence:[e:64..264] = [t:64..264]
;2)section:[e:268..311] = [t:268..311]
;3)section:[e:315..402] = [t:315..402]
;4)sentence:[e:406..523] = [t:406..523]
;5)sentence:[e:524..594] = [t:524..594]
;6)sentence:[e:595..1051] = [t:595..1051]
;7)sentence:[e:1052..1370] = [t:1052..1370]
;8)sentence:[e:1371..1551] = [t:1371..1551]
;9)sentence:[e:1552..1797] = [t:1552..1797]
;10)section:[e:1801..1846] = [t:1801..1846]

;section 0 Span:0..58
;Eur J Drug Metab Pharmacokinet. 2001 Jan-Jun;26(1-2):31-5.
(SEC
  (FRAG (NNP:[0..3] Eur) (NNP:[4..5] J) (NNP:[6..10] Drug) (NNP:[11..16] Metab)
        (NNP:[17..30] Pharmacokinet) (.:[30..31] .) (CD:[32..36] 2001)
        (HYPH:[37..41] Jan-) (CD:[41..49] Jun;26-LRB-1) (HYPH:[49..50] -)
        (LS:[50..51] 2) (-RRB-:[51..52] -RRB-) (.:[52..55] :31) (::[55..57] -5)
        (.:[57..58] .)))

;sentence 1 Span:64..264
;Interactions of melatonin with the liver microsomal cytochrome P450 system of
; rats and humans in vitro and effects on the P450 system and the
;antioxidative  status in rat liver after acute treatment.
;[80..89]:substance:"melatonin"
;[116..131]:cyp450:"cytochrome P450"
;[187..191]:cyp450:"P450"
(SENT
  (NP-HLN
    (NP
      (NP (NNS:[64..76] Interactions))
      (PP (IN:[77..79] of)
        (NP (NN:[80..89] melatonin)))
      (PP (IN:[90..94] with)
        (NP
          (NP (DT:[95..98] the) (NN:[99..104] liver) (JJ:[105..115] microsomal)
            (NML (NN:[116..126] cytochrome) (NN:[127..131] P450))
            (NN:[132..138] system))
          (PP (IN:[139..141] of)
            (NP (NNS:[143..147] rats) (CC:[148..151] and)
                (NNS:[152..158] humans)))))
      (ADJP (FW:[159..161] in) (FW:[162..167] vitro)))
    (CC:[168..171] and)
    (NP
      (NP (NNS:[172..179] effects))
      (PP (IN:[180..182] on)
        (NP
          (NP (DT:[183..186] the) (NN:[187..191] P450) (NN:[192..198] system))
          (CC:[199..202] and)
          (NP (DT:[203..206] the) (JJ:[207..220] antioxidative)
              (NN:[222..228] status))))
      (PP-LOC (IN:[229..231] in)
        (NP (NN:[232..235] rat) (NN:[236..241] liver)))
      (PP-TMP (IN:[242..247] after)
        (NP (JJ:[248..253] acute) (NN:[254..263] treatment))))
    (.:[263..264] .)))

;section 2 Span:268..311
;Klinger W, Karge E, Demme U, Kretzschmar M.
(SEC
  (FRAG (NNP:[268..275] Klinger) (NNP:[276..277] W) (,:[277..278] ,)
        (NNP:[279..284] Karge) (NNP:[285..286] E) (,:[286..287] ,)
        (NNP:[288..293] Demme) (NNP:[294..295] U) (,:[295..296] ,)
        (NNP:[297..308] Kretzschmar) (NNP:[309..311] M.)))

;section 3 Span:315..402
;Institute of Pharmacology and Toxicology, Friedrich Schiller University Jena,
; Germany.
(SEC
  (FRAG (NNP:[315..324] Institute) (IN:[325..327] of)
        (NNP:[328..340] Pharmacology) (CC:[341..344] and)
        (NNP:[345..355] Toxicology) (,:[355..356] ,) (NNP:[357..366] Friedrich)
        (NNP:[367..375] Schiller) (NNP:[376..386] University)
        (NNP:[387..391] Jena) (,:[391..392] ,) (NNP:[394..401] Germany)
        (.:[401..402] .)))

;sentence 4 Span:406..523
;In vitro melatonin binds to human and rat liver microsomal cytochrome P-450 
;(P450) according to a type II substrate.
;[415..424]:substance:"melatonin"
;[465..481]:cyp450:"cytochrome P-450"
;[484..488]:cyp450:"P450"
;[505..522]:substance:"type II substrate"
(SENT
  (S
    (NP-SBJ
      (ADJP (FW:[406..408] In) (FW:[409..414] vitro))
      (NN:[415..424] melatonin))
    (VP (VBZ:[425..430] binds)
      (PP-CLR (TO:[431..433] to)
        (NP
          (NP (JJ:[434..439] human)
            (NML-1 (-NONE-:[439..439] *P*)))
          (CC:[440..443] and)
          (NP (NN:[444..447] rat)
            (NML-1 (NN:[448..453] liver) (JJ:[454..464] microsomal)
              (NML
                (NML (NN:[465..475] cytochrome) (NN:[476..481] P-450))
                (NML (-LRB-:[483..484] -LRB-) (NN:[484..488] P450)
                     (-RRB-:[488..489] -RRB-)))))))
      (PP (VBG:[490..499] according)
        (PP (TO:[500..502] to)
          (NP (DT:[503..504] a)
            
            (NML (NN:[505..509] type) (CD:[510..512] II))
            (NN:[513..522] substrate)))))
    (.:[522..523] .)))

;sentence 5 Span:524..594
;The affinity is similar to that of  aniline with a general left-shift.
;[560..567]:substance:"aniline"
(SENT
  (S
    (NP-SBJ (DT:[524..527] The) (NN:[528..536] affinity))
    (VP (VBZ:[537..539] is)
      (ADJP-PRD (JJ:[540..547] similar)
        (PP (TO:[548..550] to)
          (NP
            (NP (DT:[551..555] that))
            (PP (IN:[556..558] of)
              (NP (NN:[560..567] aniline)))
            (PP (IN:[568..572] with)
              (NP (DT:[573..574] a) (JJ:[575..582] general) (NN:[583..587] left)
                  (HYPH:[587..588] -) (NN:[588..593] shift)))))))
    (.:[593..594] .)))

;sentence 6 Span:595..1051
;Melatonin interferes with model monooxygenase  reactions indicative of
;different P450 forms in humans and rats (in humans  according to the lower
;specific P450 content less pronounced): the strongest  inhibition was found
;for ethoxyresorufin O-deethylation, indicating the binding  to P450 1A, the
;binding to P450 2B (ethoxycoumarin O-deethylation) was less  pronounced, the
;least inhibition was found for P450 3A (ethylmorphine  N-demethylation)
;reaction.
;[595..604]:substance:"Melatonin"
;[627..640]:substance:"monooxygenase"
;[676..686]:cyp450:"P450 forms"
;[750..754]:cyp450:"P450"
;[821..836]:substance:"ethoxyresorufin"
;[880..887]:cyp450:"P450 1A"
;[904..911]:cyp450:"P450 2B"
;[913..927]:substance:"ethoxycoumarin"
;[1001..1008]:cyp450:"P450 3A"
;[1010..1023]:substance:"ethylmorphine"
(SENT
  (S
    (S
      (NP-SBJ (NN:[595..604] Melatonin))
      (VP (VBZ:[605..615] interferes)
        (PP-CLR (IN:[616..620] with)
          (NP
            (NP (NN:[621..626] model) (NN:[627..640] monooxygenase)
                (NNS:[642..651] reactions))
            (ADJP (JJ:[652..662] indicative)
              (PP (IN:[663..665] of)
                (NP
                  (NP (JJ:[666..675] different)
                     (NN:[676..680] P450) (NNS:[681..686] forms))
                  (PP-LOC (IN:[687..689] in)
                    (NP (NNS:[690..696] humans) (CC:[697..700] and)
                        (NNS:[701..705] rats)))
                  (PRN (-LRB-:[706..707] -LRB-)
                    (FRAG
                      (PP-LOC (IN:[707..709] in)
                        (NP
                          (NP (NNS:[710..716] humans))
                          (PP (VBG:[718..727] according)
                            (PP (TO:[728..730] to)
                              (NP (DT:[731..734] the) (JJR:[735..740] lower)
                                  (JJ:[741..749] specific) (NN:[750..754] P450)
                                  (NN:[755..762] content))))))
                      (ADJP (RBR:[763..767] less) (JJ:[768..778] pronounced)))
                    (-RRB-:[778..779] -RRB-)))))))))
    (::[779..780] :)
    (S
      (NP-SBJ-2 (DT:[781..784] the) (JJS:[785..794] strongest)
                (NN:[796..806] inhibition))
      (VP (VBD:[807..810] was)
        (VP (VBN:[811..816] found)
          (NP-2 (-NONE-:[816..816] *))
          (PP (IN:[817..820] for)
            (NP (NN:[821..836] ethoxyresorufin) (NN:[837..851] O-deethylation)))
          (,:[851..852] ,)
          (S-ADV
            (NP-SBJ (-NONE-:[852..852] *))
            (VP (VBG:[853..863] indicating)
              (NP
                (NP (DT:[864..867] the) (NN:[868..875] binding))
                (PP (TO:[877..879] to)
                  (NP (NN:[880..884] P450) (NN:[885..887] 1A))))))
          (,:[887..888] ,)
          (S-ADV
            (S
              (NP-SBJ
                (NP (DT:[889..892] the) (NN:[893..900] binding))
                (PP (TO:[901..903] to)
                  (NP (NN:[904..908] P450) (NN:[909..911] 2B)))
                (PRN (-LRB-:[912..913] -LRB-)
                  (NP (NN:[913..927] ethoxycoumarin)
                      (NN:[928..942] O-deethylation))
                  (-RRB-:[942..943] -RRB-)))
              (VP (VBD:[944..947] was)
                (ADJP-PRD (RBR:[948..952] less) (JJ:[954..964] pronounced))))
            (,:[964..965] ,)
            (S
              (NP-SBJ-1 (DT:[966..969] the) (JJS:[970..975] least)
                        (NN:[976..986] inhibition))
              (VP (VBD:[987..990] was)
                (VP (VBN:[991..996] found)
                  (NP-1 (-NONE-:[996..996] *))
                  (PP (IN:[997..1000] for)
                    (NP
                      (NML (NN:[1001..1005] P450) (NN:[1006..1008] 3A))
                      (PRN (-LRB-:[1009..1010] -LRB-)
                        (NP (NN:[1010..1023] ethylmorphine)
                            (NN:[1025..1040] N-demethylation))
                        (-RRB-:[1040..1041] -RRB-))
                      (NN:[1042..1050] reaction))))))))))
    (.:[1050..1051] .)))

;sentence 7 Span:1052..1370
;The oxidase function was also inhibited: luminol  amplified chemiluminescence
;was more inhibited than the lucigenin amplified one,  hydrogen peroxide
;formation was inhibited at concentrations higher than 10(-4)  M, microsomal
;NADPH/Fe stimulated lipid peroxidation was inhibited at  concentrations
;higher than 10(5) M.
;[1056..1063]:substance:"oxidase"
;[1093..1100]:substance:"luminol"
;[1158..1167]:substance:"lucigenin"
;[1184..1201]:substance:"hydrogen peroxide"
;[1256..1262]:quantitative-value:"10(-4)"
;[1264..1265]:quantitative-units:"M"
;[1278..1283]:substance:"NADPH"
;[1284..1286]:substance:"Fe"
;[1362..1367]:quantitative-value:"10(5)"
;[1368..1369]:quantitative-units:"M"
(SENT
  (S
    (S
      (NP-SBJ-3 (DT:[1052..1055] The) (NN:[1056..1063] oxidase)
                (NN:[1064..1072] function))
      (VP (VBD:[1073..1076] was)
        (ADVP (RB:[1077..1081] also))
        (VP (VBN:[1082..1091] inhibited)
          (NP-3 (-NONE-:[1091..1091] *)))))
    (::[1091..1092] :)
    (S
      (S
        (NP-SBJ
          (ADJP (NN:[1093..1100] luminol) (VBN:[1102..1111] amplified))
          (NN:[1112..1129] chemiluminescence))
        (VP (VBD:[1130..1133] was)
          (ADJP-PRD
            (ADJP (RBR:[1134..1138] more) (VBN:[1139..1148] inhibited))
            (PP (IN:[1149..1153] than)
              (NP (DT:[1154..1157] the)
                (ADJP (NN:[1158..1167] lucigenin) (VBN:[1168..1177] amplified))
                (NN:[1178..1181] one))))))
      (,:[1181..1182] ,)
      (S
        (NP-SBJ-1
          (NML (NN:[1184..1192] hydrogen) (NN:[1193..1201] peroxide))
          (NN:[1202..1211] formation))
        (VP (VBD:[1212..1215] was)
          (VP (VBN:[1216..1225] inhibited)
            (NP-1 (-NONE-:[1225..1225] *))
            (PP (IN:[1226..1228] at)
              (NP
                (NP (NNS:[1229..1243] concentrations))
                (ADJP
                  (ADJP (JJR:[1244..1250] higher))
                  (PP (IN:[1251..1255] than)
                    (NP (CD:[1256..1262] 10-LRB--4-RRB-) (NN:[1264..1265] M)))))))))
      (,:[1265..1266] ,)
      (S
        (NP-SBJ-2
          (ADJP
            (NML
              (NML (JJ:[1267..1277] microsomal) (NN:[1278..1283] NADPH))
              (SYM:[1283..1284] /)
              (NML (NN:[1284..1286] Fe)))
            (VBN:[1287..1297] stimulated))
          (NN:[1298..1303] lipid) (NN:[1304..1316] peroxidation))
        (VP (VBD:[1317..1320] was)
          (VP (VBN:[1321..1330] inhibited)
            (NP-2 (-NONE-:[1330..1330] *))
            (PP (IN:[1331..1333] at)
              (NP
                (NP (NNS:[1335..1349] concentrations))
                (ADJP
                  (ADJP (JJR:[1350..1356] higher))
                  (PP (IN:[1357..1361] than)
                    (NP (CD:[1362..1367] 10-LRB-5-RRB-) (NN:[1368..1369] M))))))))))
    (.:[1369..1370] .)))

;sentence 8 Span:1371..1551
;In vivo melatonin prolonged hexobarbital  sleeping time in rats in a dose
;dependent manner (ip. co-administration of 1, 5  and 20 mg/kg b.w. melatonin
;with 100 mg/kg hexobarbital).
;[1379..1388]:substance:"melatonin"
;[1399..1411]:substance:"hexobarbital"
;[1488..1489]:quantitative-value:"1"
;[1491..1492]:quantitative-value:"5"
;[1498..1500]:quantitative-value:"20"
;[1501..1506]:quantitative-units:"mg/kg"
;[1512..1521]:substance:"melatonin"
;[1527..1530]:quantitative-value:"100"
;[1531..1536]:quantitative-units:"mg/kg"
;[1537..1549]:substance:"hexobarbital"
(SENT
  (S
    (NP-SBJ
      (ADJP (FW:[1371..1373] In) (FW:[1374..1378] vivo))
      (NN:[1379..1388] melatonin))
    (VP (VBD:[1389..1398] prolonged)
      (NP (NN:[1399..1411] hexobarbital) (NN:[1413..1421] sleeping)
          (NN:[1422..1426] time))
      (PP-LOC (IN:[1427..1429] in)
        (NP (NNS:[1430..1434] rats)))
      (PP (IN:[1435..1437] in)
        (NP (DT:[1438..1439] a)
          (ADJP (NN:[1440..1444] dose) (JJ:[1445..1454] dependent))
          (NN:[1455..1461] manner)))
      (PRN (-LRB-:[1462..1463] -LRB-)
        (NP
          (NP (JJ:[1463..1466] ip.) (AFX:[1467..1469] co) (HYPH:[1469..1470] -)
              (NN:[1470..1484] administration))
          (PP (IN:[1485..1487] of)
            (NP
              (NP
                (NP
                  (NML
                    (NML (CD:[1488..1489] 1)
                      (NML-1 (-NONE-:[1489..1489] *P*)))
                    (PP-2 (-NONE-:[1489..1489] *P*)))
                  (NML-3 (-NONE-:[1489..1489] *P*)))
                (,:[1489..1490] ,)
                (NP
                  (NML
                    (NML (CD:[1491..1492] 5)
                      (NML-1 (-NONE-:[1492..1492] *P*)))
                    (PP-2 (-NONE-:[1492..1492] *P*)))
                  (NML-3 (-NONE-:[1492..1492] *P*)))
                (CC:[1494..1497] and)
                (NP
                  (NML
                    (NML (CD:[1498..1500] 20)
                      (NML-1 (NN:[1501..1503] mg)))
                    (PP-2 (SYM:[1503..1504] /)
                      (NP (NN:[1504..1506] kg) (NN:[1507..1511] b.w.))))
                  (NML-3 (NN:[1512..1521] melatonin))))
              (PP (IN:[1522..1526] with)
                (NP
                  (NML
                    (NML (CD:[1527..1530] 100) (NN:[1531..1533] mg))
                    (PP (SYM:[1533..1534] /)
                      (NP (NN:[1534..1536] kg))))
                  (NN:[1537..1549] hexobarbital))))))
        (-RRB-:[1549..1550] -RRB-)))
    (.:[1550..1551] .)))

;sentence 9 Span:1552..1797
;Immediately after  awakening the animals were sacrificed: a small increase in
;P450 concentrations  cannot be explained, no changes in P450 monooxygenase or
;oxidase activities nor  in microsomal lipid peroxidation or GSH status could
;be observed.
;[1630..1634]:cyp450:"P450"
;[1686..1704]:substance:"P450 monooxygenase"
;[1686..1690]...[1708..1715]:substance:"P450"..."oxidase"
;[1768..1771]:substance:"GSH"
(SENT
  (S
    (S
      (SBAR-ADV
        (ADVP (RB:[1552..1563] Immediately))
        (IN:[1564..1569] after)
        (S
          (NP-SBJ (-NONE-:[1569..1569] *))
          (VP (VBG:[1571..1580] awakening))))
      (NP-SBJ-1 (DT:[1581..1584] the) (NNS:[1585..1592] animals))
      (VP (VBD:[1593..1597] were)
        (VP (VBN:[1598..1608] sacrificed)
          (NP-1 (-NONE-:[1608..1608] *)))))
    (::[1608..1609] :)
    (S
      (S
        (NP-SBJ-2
          (NP (DT:[1610..1611] a) (JJ:[1612..1617] small)
              (NN:[1618..1626] increase))
          (PP (IN:[1627..1629] in)
            (NP (NN:[1630..1634] P450) (NNS:[1635..1649] concentrations))))
        (VP (MD:[1651..1657] cannot)
          (VP (VB:[1658..1660] be)
            (VP (VBN:[1661..1670] explained)
              (NP-2 (-NONE-:[1670..1670] *))))))
      (,:[1670..1671] ,)
      (S
        (NP-SBJ-5
          (NP (DT:[1672..1674] no) (NNS:[1675..1682] changes))
          (PP
            (PP (IN:[1683..1685] in)
              (NP
                (NP
                  (NML
                    (NML-3 (NN:[1686..1690] P450))
                    (NN:[1691..1704] monooxygenase))
                  (NML-4 (-NONE-:[1704..1704] *P*)))
                (CC:[1705..1707] or)
                (NP
                  (NML
                    (NML-3 (-NONE-:[1707..1707] *P*))
                    (NN:[1708..1715] oxidase))
                  (NML-4 (NNS:[1716..1726] activities)))))
            (CC:[1727..1730] nor)
            (PP (IN:[1732..1734] in)
              (NP
                (NP (JJ:[1735..1745] microsomal) (NN:[1746..1751] lipid)
                    (NN:[1752..1764] peroxidation))
                (CC:[1765..1767] or)
                (NP (NN:[1768..1771] GSH) (NN:[1772..1778] status))))))
        (VP (MD:[1779..1784] could)
          (VP (VB:[1785..1787] be)
            (VP (VBN:[1788..1796] observed)
              (NP-5 (-NONE-:[1796..1796] *)))))))
    (.:[1796..1797] .)))

;section 10 Span:1801..1846
;PMID: 11554431 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1801..1805] PMID) (::[1805..1806] :) (CD:[1807..1815] 11554431)
        (IN:[1816..1817] -LSB-) (NNP:[1817..1823] PubMed) (HYPH:[1824..1825] -)
        (JJ:[1826..1833] indexed) (IN:[1834..1837] for)
        (NNP:[1838..1846] MEDLINE-RSB-)))
